Dravo Bay’s Anavex Life Sciences AVXL Stock Holding History

Dravo Bay’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-300	Closed	-$3.69K	–	48
2022 Q1	$3.69K	Buy	+300	New	+$3.69K	﹤0.01%	131

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Dravo Bay's AVXL Position: Q2 2022 in Review

Dravo Bay sold out of Anavex Life Sciences (AVXL) in Q2 2022, closing a stake of 300 shares — an estimated $3.69K sold.

Dravo Bay first reported a position in AVXL in Q1 2022 and held it in 1 quarter. The position peaked at $3.69K in Q1 2022. 150 funds tracked by Wall St. Rank hold AVXL as of Q2 2022.

Dravo Bay reported no remaining Anavex Life Sciences position as of Q2 2022 after selling out during the quarter.
Dravo Bay sold 300 Anavex Life Sciences shares in Q2 2022, an estimated $3.69K.
Dravo Bay first reported a position in Anavex Life Sciences in Q1 2022 and held it in 1 quarter.
Dravo Bay's Anavex Life Sciences position peaked at $3.69K in Q1 2022.
150 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2022.

Based on Dravo Bay's 13F filing for Q2 2022, filed 15 Aug 2022.